Movement Alert｜Insmed Rises 5.95% in Regular Trading, PAH Inhalation Therapy Phase 3 Trial Shows Positive Progress

Market Focus06-12

On June 11, Insmed rose 5.95% in regular trading, trading at $97.6/share, with turnover of $226 million. The stock gained momentum following the company's announcement of positive developments in its Phase 3 clinical trial for an inhaled therapy targeting pulmonary arterial hypertension (PAH).

Insmed disclosed that its Treprostinil Palmitil Inhalation Powder (TPIP) Phase 3 clinical trial is progressing with ongoing patient enrollment. The study evaluates the efficacy of once-daily inhaled dosing in improving daily activity capacity in adult PAH patients. If successful, this late-stage trial would diversify Insmed's revenue streams and position the company to compete directly with Johnson & Johnson and United Therapeutics in the PAH market.

The positive clinical momentum adds to recent bullish sentiment around Insmed. RBC Capital Markets maintained an Outperform rating with a $195 price target, while highlighting strong physician conviction and early launch momentum for Brensocatib (marketed as Brinsupri), citing compelling efficacy with no new exacerbations and strong safety data across more than 60 patients. Analyst consensus reflects an average Buy rating with a mean target of $199.52.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1151384337?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-12 00:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1151384337","market":"us","top_or_hot":-1,"title":"Movement Alert｜Insmed Rises 5.95% in Regular Trading, PAH Inhalation Therapy Phase 3 Trial Shows Positive Progress","media":"Market Focus","content":"<p><p>On June 11, Insmed rose 5.95% in regular trading, trading at $97.6/share, with turnover of $226 million. The stock gained momentum following the company's announcement of positive developments in its Phase 3 clinical trial for an inhaled therapy targeting pulmonary arterial hypertension (PAH).</p><p>Insmed disclosed that its Treprostinil Palmitil Inhalation Powder (TPIP) Phase 3 clinical trial is progressing with ongoing patient enrollment. The study evaluates the efficacy of once-daily inhaled dosing in improving daily activity capacity in adult PAH patients. If successful, this late-stage trial would diversify Insmed's revenue streams and position the company to compete directly with Johnson & Johnson and United Therapeutics in the PAH market.</p><p>The positive clinical momentum adds to recent bullish sentiment around Insmed. RBC Capital Markets maintained an Outperform rating with a $195 price target, while highlighting strong physician conviction and early launch momentum for Brensocatib (marketed as Brinsupri), citing compelling efficacy with no new exacerbations and strong safety data across more than 60 patients. Analyst consensus reflects an average Buy rating with a mean target of $199.52.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Insmed Rises 5.95% in Regular Trading, PAH Inhalation Therapy Phase 3 Trial Shows Positive Progress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Insmed Rises 5.95% in Regular Trading, PAH Inhalation Therapy Phase 3 Trial Shows Positive Progress\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-12 00:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 11, Insmed rose 5.95% in regular trading, trading at $97.6/share, with turnover of $226 million. The stock gained momentum following the company's announcement of positive developments in its Phase 3 clinical trial for an inhaled therapy targeting pulmonary arterial hypertension (PAH).</p><p>Insmed disclosed that its Treprostinil Palmitil Inhalation Powder (TPIP) Phase 3 clinical trial is progressing with ongoing patient enrollment. The study evaluates the efficacy of once-daily inhaled dosing in improving daily activity capacity in adult PAH patients. If successful, this late-stage trial would diversify Insmed's revenue streams and position the company to compete directly with Johnson & Johnson and United Therapeutics in the PAH market.</p><p>The positive clinical momentum adds to recent bullish sentiment around Insmed. RBC Capital Markets maintained an Outperform rating with a $195 price target, while highlighting strong physician conviction and early launch momentum for Brensocatib (marketed as Brinsupri), citing compelling efficacy with no new exacerbations and strong safety data across more than 60 patients. Analyst consensus reflects an average Buy rating with a mean target of $199.52.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INSM","symbol_name":"Insmed","start_time":0,"source_url":"","article_id":"1151384337","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1151384337","pubTimestamp":1781194529,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 11, Insmed rose 5.95% in regular trading, trading at $97.6/share, with turnover of $226 million. The stock gained momentum following the company's announcement of positive developments in its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"INSM":"Insmed"},"translate_title":"动静快讯|Insmed常规交易涨5.95%PAH吸入疗法3期试验显示积极进展","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INSM":1},"content_text":"On June 11, Insmed rose 5.95% in regular trading, trading at $97.6/share, with turnover of $226 million. The stock gained momentum following the company's announcement of positive developments in its Phase 3 clinical trial for an inhaled therapy targeting pulmonary arterial hypertension (PAH).Insmed disclosed that its Treprostinil Palmitil Inhalation Powder (TPIP) Phase 3 clinical trial is progressing with ongoing patient enrollment. The study evaluates the efficacy of once-daily inhaled dosing in improving daily activity capacity in adult PAH patients. If successful, this late-stage trial would diversify Insmed's revenue streams and position the company to compete directly with Johnson & Johnson and United Therapeutics in the PAH market.The positive clinical momentum adds to recent bullish sentiment around Insmed. RBC Capital Markets maintained an Outperform rating with a $195 price target, while highlighting strong physician conviction and early launch momentum for Brensocatib (marketed as Brinsupri), citing compelling efficacy with no new exacerbations and strong safety data across more than 60 patients. Analyst consensus reflects an average Buy rating with a mean target of $199.52.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1151384337","isCrawlerRequest":true}